Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated

Dienstag, 16.10.2018 17:35 von DGAP - Aufrufe: 65

Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated 16-Oct-2018 / 16:30 GMT/BST

Hardman & Co: Four components integrated

AVO's goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones has boosted confidence greatly, and the group remains on track with its strategy. AVO has successfully integrated the four types of structures that constitute the LIGHT accelerator and has overcome technical challenges. The proton beam has been recorded at an energy of 52MeV, sufficient to treat superficial tumours. With the distribution agreement in place for SE Asia, partnerships with both RaySearch and the STFC, and strengthening of its financing structure, AVO is now on a much firmer footing.

Please click here for the full report:


To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

734265  16-Oct-2018 

Mehr Nachrichten kostenlos abonnieren
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptieren Sie die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.